Abiopharma

🔍 Lowenkron Melissa B (Executive)

Company: Fossil Group, Inc. (FOSL)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Sold 11,641 shares of Common Stock at $5.4 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 91,766.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 150,000 shares of Performance Stock Units (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 220,000.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3, F3, F3, F3

Footnotes:

• F1: Includes 5,258 Restricted Stock Units subject to a vesting schedule.
• F2: Each performance restricted stock unit (PRSU) represents a contingent right to receive one share of Fossil Group, Inc. (the Issuer) common stock (the Common Stock).
• F3: On April 15, 2026, the Issuer granted 150,000 PRSUs to the reporting person under the Issuers 2024 Long-Term Incentive Plan. These PRSUs will vest into shares of Common Stock of the Issuer on a 1-for-1 basis yearly, in three equal installments. Each yearly vest is subject to an increase in the number of shares to be issued based on the average fair market value of a share of the Common Stock over the last thirty consecutive trading days of the most recent calendar year prior to the vesting date. If the average fair market value is between $4.25 to $5.99, the number of shares to be issued upon an annual vesting of PRSUs will be increased by 20%. If the average fair market value is between $6.00 and $7.74, the number of shares to be issued upon an annual vesting of PRSUs will be increased by 30%. If the average fair market value is $7.75 or above, the number of shares issued upon an annual vesting of PRSUs will be increased by 50%.